A special issue on Nursing: Current Scenario and Future Development - Articles are invited.


Authors: I Ketut Adnyana, Alkilany Salem Abuzaid, Elin Yulinah Iskandar, Neng Fisheri Kurniati

Int J Med Res Health Sci.2016;5(1):23-28 | pdf PDF Full Text

Background: Obesity is a disorder of lipid metabolism and the enzyme involved in this process could be selectively targeted to develop anti  obesity drugs. Inhibition of digestive enzymes is one of the most widely studies mechanisms used  to  determine  the  hypolipidemic  and  hypoglycemic  agent  of  natural products for anti-obesity agent screening. Aims: To evaluate the inhibitory potential of G. mangostana extract, xanthone and α-mangosteen compound toward pancreatic lipase and α-amylase enzyme as once of anti-obesity mechanism. Material and Methods: The IC50 value of the mangosteen pericarp extract, xanthone, and α-mangosteen toward pancreatic lipase and α-amylase were determined in vitro compared to orlistat and acarbose as standard drugs. Results: Mangosteen pericarp extract contains phenol, terpenoid, saponin, flavonoid and tannin. Mangosteen pericarp extract is a more active compound in inhibiting the PPL activity compared to α-mangosteen, and xanthone. Mangosteen pericarp extract shows the higher activity compared to xanthone but still lower activity compared to α-mangosteen. However, its activity is still lower than standard drugs. Conclusions: Our in vitro, confirmed that the mangosteen pericarp extract has the phytochemical bioactive content that possesses anti-obesity potential through pancreatic lipase and α-amylase inhibitory activity.

Keywords: Anti-obesity, Pancreatic lipase, α-amylase, Mangosteen pericarp      extract, Xanthone, α-mangosteen

International Journal of Medical Research & Health Sciences © 2012-16 [Last updated: July 2016] by AspiringDigital